

DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LIMITED**Balance Sheet**

As at 31st Mar		Notes No	2015	2015	2014	2014
			USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES						
Shareholders' Funds						
Share capital	1		100,001	6,200	1	0
Reserves & surplus	2		7,073,164	442,123	7,083,530	424,374
			7,173,165	448,323	7,083,531	424,374
Current liabilities						
Trade payables	3		14,194	887	3,993	239
			7,187,359	449,210	7,087,524	424,614
II. ASSETS						
Non-current assets						
Non-current investments	4		7,162,523	447,658	7,087,523	424,614
			7,162,523	447,658	7,087,523	424,614
Current assets						
Cash & bank balances	5		24,835	1,552	-	-
Short-term loans and advances	6		1	0	1	0
			24,836	1,552	1	0
Total			7,187,359	449,210	7,162,524	424,614

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LIMITED**Statement of Profit and Loss**

For the year ended 31st March,	Notes No	2015	2015	2014	2014
		USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES					
Other expenses	7	10,366	640	3,993	247
Total expenses		10,366	640	3,993	247
Profit for the Year		(10,366)	(640)	(3,993)	(247)

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

CASH FLOW STATEMENT

Cash flow Statement for the Year Ended	2015	2015	2014	2014
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(10,366)	(640)	(3,993)	(247)
Operating profit before working capital changes	(10,366)	(640)	(3,993)	(247)
Adjustments for :				
(Increase)/Decrease in trade and other receivables	-	-	(1)	(0)
Increase/(Decrease) in trade and other payables	10,201	624	3,993	241
Net cash inflow/(outflow) in course of operating activities	(165)	(17)	(1)	(5)
B. Cash flow arising from investing activities :				
(Purchase)/sale of investments (net)(Including in Subsidiaries)	(75,000)	(4,586)	-	-
Net cash inflow/(outflow) in course of investing activities	(75,000)	(4,586)	-	-
C. Cash flow arising from financing activities :				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	100,000	6,200	1	0
Net cash inflow/(outflow) in course of financing activities	100,000	6,200	1	0
D. Foreign currency translation difference arising on consolidation		(45)		5
Net Increase in cash & cash equivalents (A+B+C+D)	24,835	1,552	-	0
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	24,835	1,552	-	0

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in Accounting Standard 3 (AS-3)- "Cash Flow Statements"

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date : 29th April, 2015

DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LIMITED**Notes to the Financial Statements**

As at 31st Mar	2015	2015	2014	2014
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
Equity Share Capital	-	-	-	-
	-	-	-	-
Issued & Subscribed				
1,00,001 Equity Shares of USD 1 each	100,001	6,200.06	1	0
(Previous Year 1 Equity Shares of USD 1 each)	100,001	6,200.06	1	0
Paid up				
1,00,001 Equity Shares of USD 1 each	100,001	6,200.06	1	0
(Previous Year 1 Equity Shares of USD 1 each)	100,001	6,200.06	1	0

1) The Company has only one class of shares referred to as equity shares having par value of ` 1. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

3) The details of shares held by holding/ultimate holding company and/or their subsidiaries/associates :

As at 31st Mar	2015	2015	2014	2014
Name of the shareholder	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Jubilant Life Sciences Ltd- Holding Company	100,001	6,200.06	1	0

4) The details of shareholders holding more than 5% shares as at 31st March,2015 is set out below:

As at 31st Mar	2015	2015	2014	2014
Name of the shareholder	No of shares	% held	No of shares	% held
Jubilant Life Sciences Ltd- Holding Company	100,001	100%	1	100%

5) The reconciliation of the number of shares outstanding as at 31st March,2015 and 31st March,2014 is set out below:

As at 31st Mar	2015	2015	2014	2014
Particulars	No	INR (' In Thousands)	No	INR (' In Thousands)
Numbers of shares at the beginning	1	0	-	-
Add: Shares issued during the year	100,000	6,200	1	0
Numbers of shares at the end	100,001	6,200	1	0

DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LIMITED

Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Capital Reserve				
As per last Balance Sheet	7,087,523	437,655	-	-
Additions/Adjustment on account of Merger	-	-	7,087,523	437,655
	7,087,523	437,655	7,087,523	437,655
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	(13,034)	-	-
Foreign Currency Translation Reserve During the Year	-	18,389	-	(13,034)
	-	5,355	-	(13,034)
Surplus as per P&L Account				
As per last Balance Sheet	(3,993)	(247)	-	-
Add: Net Profit after tax transferred from Statement of Profit and Loss	(10,366)	(640)	(3,993)	(247)
	(14,359)	(887)	(3,993)	(247)
	7,073,164	442,123	7,083,530	424,374
3. TRADE PAYABLES				
Trade payables-others	14,194	887	3,993	239
	14,194	887	3,993	239
4. NON-CURRENT INVESTMENT				
Investment in Subsidiary/Fellow Subsidiaries Companies				
Jubilant Life Sciences BVI LTD				
3,927,501 equity shares of USD 1 each	3,952,898	247,056	3,952,898	236,818
Jubilant Innovation BVI LTD				
1,630,000 equity shares of USD 1 each	3,209,625	200,602	3,134,625	187,495
	7,162,523	447,658	7,087,523	424,313
5. CASH AND BANK BALANCES				
Cash and cash equivalents				
Balances with banks:				
- On current accounts	24,835	1,552	-	-
	24,835	1,552	-	-
6. SHORT TERM LOANS AND ADVANCES				
- Advance recoverable in cash & kind				
- From related parties	1	0	1	0
	1	0	1	0
7. OTHER EXPENSE				
Auditors Remuneration - As Auditors	4,109	250	-	-
Legal, professional & consultancy charges	6,092	380	3,993	247
Bank Charges	165	10	-	-
	10,366	640	3,993	247